<DOC>
	<DOCNO>NCT00033267</DOCNO>
	<brief_summary>Phase II trial study effectiveness CCI-779 treating patient mantle cell non-Hodgkin 's lymphoma . Drugs use chemotherapy use different way stop cancer cell divide stop grow die .</brief_summary>
	<brief_title>CCI-779 Treating Patients With Mantle Cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response patient previously treat mantle cell non-Hodgkin 's lymphoma treat CCI-779 . II . Determine toxic effect drug patient . III . Determine whether drug inhibits cell proliferation pathway patient . OUTLINE : Patients receive CCI-779 IV 30 minute day 1 , 8 , 15 , 22 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients stable disease receive maximum 6 course . Patients partial response receive maximum 12 course . Patients complete response ( CR ) receive 2 additional course beyond CR . Patients follow every 3 month 1 year , every 4 month 1 year , every 6 month 1 year , annually 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologically confirm mantle cell nonHodgkin 's lymphoma ( MCL ) Relapsed , refractory , stable disease prior chemotherapy , radiotherapy , immunotherapy Unidimensionally measurable lymph node lesion At least 2.0 cm CT scan MRI OR least 1.5 cm physical exam One follow measurement parameter may use : Splenic enlargement may use measurement parameter spleen palpable least 3.0 cm across left costal margin Malignant lymphocytosis may use measurement parameter absolute lymphocyte count least 5,000/mm^3 No know CNS involvement ( parenchymal mass leptomeningeal involvement ) Performance status ECOG 02 At least 3 month See Disease Characteristics Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 75,000/mm^3 Hemoglobin ≥ 8 g/dL Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) Direct bilirubin ≤ 1.5 time ULN AST ≤ 3 time ULN ( 5 time ULN liver metastasis present ) Creatinine ≤ 2 time ULN No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Cholesterol ≤ 350 mg/dL Triglycerides ≤ 400 mg/dL HIV negative No active malignancy require treatment would preclude study participation No concurrent uncontrolled illness No ongoing active infection No psychiatric illness social situation would preclude study participation Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation See Disease Characteristics Prior highdose therapy stem cell transplantation allow At least 7 day since prior immunotherapy nonmyelosuppressive biologic response modifier See Disease Characteristics See Biologic therapy At least 3 week since prior myelosuppressive chemotherapy ( 6 week nitrosoureas mitomycin ) No concurrent chemotherapy MCL Concurrent corticosteroid adrenal insufficiency allow See Disease Characteristics At least 3 week since prior radiotherapy No concurrent radiotherapy MCL Any number prior treatment allow No concurrent investigational commercial agent MCL No concurrent drug induce cytochrome p450 ( e.g. , carbamazepine , phenobarbital , phenytoin , ketoconazole , diltiazem , rifampin , terfenadine , cisapride , astemizole , pimozide ) No concurrent immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>